Financial Performance - The company's revenue for Q3 2022 was ¥155,144,733.35, a decrease of 24.82% compared to the same period last year[4] - The net profit attributable to shareholders was -¥35,382,870.93, representing a decline of 229.10% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥36,549,891.35, down 129.18% from the previous year[4] - Total operating revenue for the current period was CNY 528,322,707.98, a decrease of 13.4% compared to CNY 611,846,115.79 in the previous period[29] - Net profit for the current period was CNY -66,671,622.16, a significant decline from CNY 5,064,063.70 in the previous period, with a loss attributable to shareholders of CNY -61,784,418.74[31][32] - Basic and diluted earnings per share were both CNY -0.1243, compared to CNY 0.0083 in the previous period[32] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,447,231,568.68, an increase of 6.34% compared to the end of the previous year[4] - The company's total liabilities increased to CNY 1,845,284,363.40 from CNY 1,573,968,545.44, indicating a rise in financial obligations[30] - Non-current liabilities rose significantly to CNY 1,020,913,466.12 from CNY 460,713,636.63, primarily due to an increase in long-term borrowings[30] - Shareholders' equity attributable to the parent company decreased to CNY 1,551,772,176.24 from CNY 1,612,804,238.79, reflecting a decline in retained earnings[30] - The total assets of the company reached CNY 3,447,231,568.68, compared to CNY 3,241,835,016.69 in the previous period, indicating growth in asset base[30] Cash Flow - The cash flow from operating activities showed a net outflow of -¥120,835,185.11, which is a 56.40% improvement compared to the same period last year[4] - The net cash flow from operating activities was -120,835,185.11 CNY, an improvement from -277,162,184.18 CNY in the previous year[34] - Cash inflow from operating activities totaled CNY 927,614,788.48, an increase from CNY 789,102,835.01 in the previous period[32] - The net cash flow from financing activities was ¥51,086.02 million, an increase of 14.57% year-on-year[12] - The net cash flow from financing activities was 510,860,242.56 CNY, an increase from 445,900,695.80 CNY year-over-year[34] Shareholder Information - Total number of common shareholders at the end of the reporting period is 37,903[14] - Liu Zhaogui holds 22.56% of shares, totaling 112,116,306 shares, with 87,326,306 shares under lock-up[14] - The second largest shareholder, a fund management company, holds 5.63% with 28,000,000 shares[14] - The company has a total of 87,326,306 locked shares for Liu Zhaogui, which cannot exceed 25% of his total shares during his tenure[17] - The company reported that 0 shares were released from lock-up during the current period for Liu Zhaogui and Ying Gang[17] Investment and Expenses - The company reported a significant increase in financial expenses, totaling ¥2,039.41 million, up 287.10% due to increased bank borrowings for project financing[11] - Investment income increased to ¥353.53 million, a rise of 703.18% compared to the previous year, attributed to higher returns from equity method investments[11] - The company reported a decrease in income tax expenses to ¥228.31 million, down 70.59% due to reduced profits in the reporting period[11] - Total cash inflow from investment activities was 105,647,951.82 CNY, down from 265,375,131.59 CNY year-over-year[34] - Cash outflow for investment activities totaled 392,952,470.62 CNY, compared to 509,620,687.28 CNY in the same period last year[34]

Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥373.18 million, a decrease of 7.97% compared to ¥405.48 million in the same period last year[21]. - The net profit attributable to shareholders of the listed company was a loss of approximately ¥26.40 million, a decline of 277.39% compared to a profit of ¥14.88 million in the previous year[21]. - The basic and diluted earnings per share were both -¥0.05, a decrease of 266.67% compared to ¥0.03 in the same period last year[21]. - The net profit after deducting non-recurring gains and losses was a loss of approximately ¥27.60 million, a decline of 295.14% compared to ¥14.15 million in the previous year[21]. - The total comprehensive income for the first half of 2022 was a loss of CNY 30.84 million, compared to a gain of CNY 13.72 million in the previous year[193]. - The company's operating profit turned negative at CNY -26.03 million, down from a profit of CNY 20.36 million in the previous year[192]. - The company reported a total loss of CNY 2,037,967.12 from its subsidiary in Qingshui, indicating the need for strategic adjustments in this area[96]. Cash Flow and Liquidity - The net cash flow from operating activities improved by 37.87%, amounting to a loss of approximately ¥164.66 million, compared to a loss of ¥265.03 million in the same period last year[21]. - The net cash flow from financing activities increased by 55.85%, reaching ¥438.02 million compared to ¥280.11 million in the previous year[53]. - Operating cash inflow for the first half of 2022 was CNY 556,797,594.43, an increase of 12.2% compared to CNY 496,142,165.88 in the first half of 2021[198]. - The total cash and cash equivalents at the end of the period increased to CNY 451,656,233.14 from CNY 269,467,155.97, marking a recovery in liquidity[200]. - Cash received from sales of goods and services rose to CNY 469,254,302.12, up from CNY 376,207,487.96, indicating strong revenue growth[198]. Assets and Liabilities - Total assets increased by 12.25% to approximately ¥3.64 billion, up from ¥3.24 billion at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company decreased by 1.61% to approximately ¥1.59 billion from ¥1.61 billion at the end of the previous year[21]. - Long-term borrowings increased by 98.35% year-over-year to approximately ¥859.13 million, reflecting financing for ongoing projects[60]. - Total liabilities increased to CNY 2,001,327,083.17, up from CNY 1,573,968,545.44, representing a growth of approximately 27%[183]. Research and Development - Research and development investment decreased by 10.93% to ¥34.50 million from ¥38.73 million in the previous year[53]. - The company emphasizes independent innovation and has accumulated substantial technical strength in analytical instruments, aiming to maintain its leadership position in the industry[38]. - The company has established a competitive advantage in the analytical instrument market through strong R&D capabilities and a comprehensive product line[29]. Market Position and Strategy - The company is a leader in the domestic analytical instrument industry, focusing on analysis and testing, environmental monitoring, and ecological governance, with a strong emphasis on R&D capabilities[28]. - The company operates under a direct sales model as its primary sales strategy, supplemented by a distribution model for broader market reach[37]. - The company is positioned to benefit from the trend of domestic substitution in the high-end analytical instrument market, as reliance on imports decreases[38]. - The company is focusing on expanding its market presence in environmental protection equipment and services, particularly in wastewater treatment and solid waste management[96]. Subsidiaries and Acquisitions - The company has completed the acquisition of Suzhou Tianrui Environmental Technology Co., Ltd. for ¥9,725.06 million, achieving 84.09% of the expected investment[77]. - The company’s subsidiary, Tianrui Environment, has established a closed-loop service system in environmental protection, covering monitoring, diagnosis, treatment, and maintenance[46]. - The company has established a subsidiary in Hubei with an investment of 19 million CNY to focus on environmental product development and consulting[103]. Risks and Challenges - The company faces operational risks from the PPP business model due to large investment amounts and long cooperation periods, which may affect profitability[113]. - The company emphasizes the importance of innovation and aims to enhance its core competitiveness to address market competition risks[111]. - The company plans not to distribute cash dividends or issue bonus shares for the semi-annual period[119]. Shareholder Information - The company’s total share capital is 496,990,870 shares, with 77.57% being unrestricted shares[161]. - Liu Zhaogui holds 23.41% of the shares, totaling 116,326,306 shares, with 29,000,000 shares under sale conditions[167]. - The largest shareholder, Liu Zhaogui, has not changed his holdings during the reporting period[167].

Financial Performance - Revenue for Q1 2022 was CNY 196,426,783.79, a decrease of 6.20% compared to CNY 209,411,764.69 in the same period last year[3] - Net profit attributable to shareholders was CNY 9,451,237.79, down 38.42% from CNY 15,347,795.32 year-on-year[3] - Total operating revenue for Q1 2022 was CNY 196.43 million, a decrease of 6.4% compared to CNY 209.41 million in Q1 2021[20] - Net profit for Q1 2022 was CNY 9.36 million, a decline of 38.5% from CNY 15.22 million in Q1 2021[21] - Earnings per share for Q1 2022 was CNY 0.019, compared to CNY 0.0309 in Q1 2021[22] Cash Flow - Net cash flow from operating activities was negative CNY 54,461,417.24, a decline of 132.30% compared to negative CNY 23,443,996.87 in the previous year[3] - The net cash flow from operating activities was -54,461,417.24 CNY, compared to -23,443,996.87 CNY in the previous year, indicating a decline in operational performance[25] - Total cash inflow from financing activities was 111,026,521.46 CNY, down from 227,993,529.57 CNY year-over-year, reflecting reduced financing activities[26] - The total cash and cash equivalents at the end of the period were 297,891,372.25 CNY, a decrease from 438,516,403.86 CNY in the previous year[26] - The cash outflow from investing activities was 118,006,712.24 CNY, significantly lower than 257,218,608.36 CNY in the same period last year, indicating a reduction in investment expenditures[25] Assets and Liabilities - Total assets increased by 5.00% to CNY 3,404,074,535.12 from CNY 3,241,835,016.69 at the end of the previous year[3] - Total assets as of Q1 2022 amounted to CNY 3.40 billion, an increase from CNY 3.24 billion in the previous year[18] - Total liabilities reached CNY 1.73 billion in Q1 2022, up from CNY 1.57 billion in Q1 2021[18] - Long-term borrowings increased to CNY 524.33 million in Q1 2022, compared to CNY 433.14 million in the same period last year[18] Operational Costs - Total operating costs for Q1 2022 were CNY 189.19 million, down 1.5% from CNY 192.75 million in the same period last year[20] - The company paid 62,517,952.61 CNY to employees, up from 55,062,734.29 CNY, indicating increased labor costs[25] - The cash outflow for purchasing goods and services was 176,034,123.65 CNY, compared to 160,938,109.72 CNY in the previous year, reflecting higher operational costs[25] Investments - Investment income dropped by 69.32% to CNY 100,684.93, primarily due to reduced returns from capital-protected financial products[6] - Cash outflows from investment activities decreased by 54.12% to CNY 118,006,712.24, reflecting reduced fixed asset and external investments[7] - The cash inflow from investment activities was 35,327,559.52 CNY, compared to 34,871,335.35 CNY in the previous year, showing a slight increase[25] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 49,561, with the largest shareholder holding 23.41% of the shares[8] - The company reported a total of 111,543,406 restricted shares at the end of the period, with 81,577 shares newly restricted[13] Miscellaneous - The company received government subsidies amounting to CNY 677,923.10 during the reporting period[5] - The company is focused on maintaining a stable financial position while exploring new market opportunities and product developments[16] - The company did not conduct an audit for the first quarter report[27]

Financial Performance - The company reported a net profit attributable to shareholders of -74.435 million yuan in 2021, a significant decline of 452.69% year-on-year, primarily due to substantial goodwill impairment and increased operating expenses [4]. - The company's operating revenue for 2021 was ¥958,340,608.40, representing a 2.42% increase compared to ¥935,696,717.93 in 2020 [26]. - The net profit attributable to shareholders in 2021 was -¥74,435,026.16, a decrease of 452.69% from ¥21,105,083.14 in 2020 [26]. - The net cash flow from operating activities was -¥503,828,082.07 in 2021, down 462.83% from ¥138,859,567.05 in 2020 [26]. - The total assets at the end of 2021 were ¥3,241,835,016.69, an increase of 26.41% from ¥2,564,439,469.59 at the end of 2020 [26]. - The company reported a basic earnings per share of -¥0.15 in 2021, a decline of 400.00% from ¥0.05 in 2020 [26]. - The total non-operating income for 2021 was ¥14,386,727.25, significantly lower than ¥57,189,568.40 in 2020 [32]. - The company experienced a quarterly revenue of ¥346,494,492.61 in Q4 2021, which was the highest among the four quarters [29]. - The net profit attributable to shareholders in Q1 2021 was ¥15,347,795.32, but turned negative in subsequent quarters, culminating in -¥78,567,185.46 in Q4 [29]. - The company's total liabilities increased, leading to a decrease in net assets attributable to shareholders by 4.70% to ¥1,612,804,238.79 at the end of 2021 [26]. - The company has indicated uncertainty regarding its ability to continue as a going concern due to negative net profits in recent years [26]. Market Position and Competition - The company faces risks from intensified market competition, particularly from international firms like Thermo Fisher and Shimadzu, which may lead to reduced market share and lower gross margins [7]. - The company plans to continue enhancing its industry position and business competitiveness to improve operational performance despite the challenges faced [4]. - The company has formed stable partnerships with numerous well-known enterprises, enhancing its market competitiveness through collaborative synergies [44]. - The environmental protection industry is experiencing rapid growth due to increased government investment and policy support, positioning the company favorably within this sector [39]. - The company is a leader in the domestic analytical instrument industry, focusing on analysis detection, environmental monitoring, ecological governance, and related services [59]. Research and Development - The company is committed to advancing its research and development capabilities to maintain a competitive edge in the analytical instrument market [60]. - The company has established a rigorous R&D process divided into four stages: concept initiation, planned development, prototype validation, and product launch [64]. - The company has invested 30 million RMB in R&D for new technologies in environmental monitoring and analysis [72]. - The company is investing 100 million yuan in R&D for the next fiscal year to enhance product capabilities and technological advancements [75]. - The company has outlined a strategic goal to achieve a 30% increase in net profit for the next fiscal year [76]. - The company has successfully obtained 163 patents, including 45 invention patents and 118 utility model patents, enhancing its competitive edge in the market [77]. - The company has developed multiple software applications for its products, including the "VOCs Online Monitoring System Application Software V4.0," which was launched on October 15, 2017 [88]. - The company is focusing on research and development of innovative technologies to improve testing accuracy and efficiency, which is anticipated to strengthen its competitive position [83]. Product Development and Innovation - New product launches include the EDX3500 and EDX8800 spectrometers, which are expected to contribute an additional 10% to the annual revenue [73]. - The introduction of a new line of food safety testing instruments is set to launch in Q2 2022, targeting a market size of 500 million yuan [75]. - The company has introduced a new automatic monitoring system for water quality, expected to capture a significant share of the environmental monitoring market [81]. - The company is actively developing new technologies, with 15 patents granted in 2021, including innovations in X-ray fluorescence and gas chromatography [75]. - The company has developed a dual optical path colorimetric technology that significantly improves measurement stability by eliminating deviations caused by changes in light source intensity or background [98]. - The introduction of a non-contact optical quantitative sensor has reduced the cost of online water quality analyzers while ensuring sample accuracy [98]. - The company has implemented high-speed mass spectrometry data acquisition technology, significantly improving the performance metrics of mass spectrometers [98]. Strategic Acquisitions and Partnerships - The company is exploring potential acquisitions to enhance its technology portfolio and expand its capabilities in analytical instrumentation [72]. - A strategic acquisition of a smaller competitor is anticipated to be completed by Q3 2022, expected to increase market share by 5% [74]. - The company has completed the acquisition of 100% equity in Suzhou Wending Environmental Technology Co., Ltd. for 135 million, integrating it as a wholly-owned subsidiary [165]. - The company is focused on expanding its market presence through strategic acquisitions and establishing new subsidiaries in the environmental technology sector [164]. - The company has established a new subsidiary in Hunan with an investment of 10 million yuan to develop medical devices and related technologies [172]. Financial Management and Investment - The company has a procurement model that includes long-term partnerships with several well-known suppliers for core components and key raw materials, ensuring quality and cost-effectiveness [65]. - The cash inflow from financing activities increased by 63.50% to ¥862,032,594.39, mainly due to increased bank loans [126]. - The company reported a significant increase in financial expenses by 95.31% year-over-year, totaling approximately ¥22.54 million, attributed to increased bank loans for project financing [119]. - The company has a cash balance of CNY 21.90 million, which is restricted due to performance guarantees and bank account freezes [136]. - The company has pledged 99% of its equity in a subsidiary as collateral for a bank loan amounting to CNY 99 million [136]. Operational Challenges and Risks - The company has indicated uncertainty regarding its ability to continue as a going concern due to negative net profits in recent years [26]. - The company faces risks from market competition, particularly from international giants and low-end product homogenization, which affects overall industry profitability [181]. - There is a risk of talent and technology loss, which could negatively impact production and operations if key personnel leave [182]. - The company aims to minimize the impact of goodwill from acquisitions on future performance by optimizing resource allocation and maintaining competitive advantages across business segments [183]. Corporate Governance - The company held five shareholder meetings during the reporting period, all conducted in compliance with regulations, ensuring the legality and effectiveness of voting results [188]. - The board of directors consists of 9 members, including 3 independent directors, meeting the requirements of relevant laws and regulations [190]. - The company has established a transparent performance evaluation and incentive mechanism for senior management, ensuring compliance with legal standards [192]. - The company maintains an independent business operation, with no competition or unfair related transactions with the controlling shareholder [196]. - The company has a complete governance structure that complies with the requirements of the China Securities Regulatory Commission and the Shenzhen Stock Exchange [195].

Financial Performance - The company's revenue for Q3 2021 was ¥206,366,073.04, a decrease of 12.42% compared to the same period last year[3]. - The net profit attributable to shareholders was -¥10,751,321.07, representing a decline of 126.01% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥15,948,128.89, a significant decrease of 4,531.02% compared to the previous year[3]. - The basic earnings per share for Q3 2021 was -¥0.0216, down 124.17% year-on-year[3]. - The weighted average return on net assets was -0.63%, a decrease of 3.17% compared to the previous year[3]. - The company reported a net profit of CNY 5.06 million for Q3 2021, a decrease of 66.67% compared to CNY 15.12 million in Q3 2020[26]. - The net profit for Q3 2021 was CNY 5,064,063.70, a decrease from CNY 19,600,254.19 in the same period last year, representing a decline of approximately 74.1%[27]. - The net profit attributable to the parent company was CNY 4,132,159.30, down from CNY 22,751,988.84, indicating a decrease of about 81.8% year-over-year[27]. - The basic and diluted earnings per share for the current period were CNY 0.0083, compared to CNY 0.0493 in the previous year, reflecting a decline of approximately 83.2%[27]. Cash Flow - The operating cash flow net amount for the year-to-date was -¥277,162,184.18, an increase of 349.19% compared to the same period last year[3]. - Net cash flow from operating activities decreased by 349.19% to -¥27,716.22 million, attributed to increased procurement for PPP projects and related payments[11]. - Cash inflows from operating activities totaled CNY 789,102,835.01, an increase from CNY 711,837,010.37 in the previous year, marking a growth of about 10.8%[29]. - Cash outflows from operating activities amounted to CNY 1,066,265,019.19, compared to CNY 773,540,070.76 in the same period last year, representing an increase of approximately 37.9%[29]. - The net cash flow from operating activities was negative at CNY -277,162,184.18, worsening from CNY -61,703,060.39 in the previous year[29]. - The total cash inflow from investing activities was CNY 265,375,131.59, up from CNY 184,545,351.49, indicating an increase of about 43.8% year-over-year[30]. - The net cash flow from investing activities was negative at CNY -244,245,555.69, compared to CNY -124,470,248.46 in the previous year, reflecting a decline of approximately 96.1%[30]. - The net cash flow from financing activities was CNY 445,900,695.80, significantly higher than CNY 122,873,160.57 in the previous year, showing an increase of about 263.5%[30]. - The ending cash and cash equivalents balance was CNY 379,674,778.16, compared to CNY 276,310,371.77 at the end of the same period last year, representing an increase of approximately 37.4%[30]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,259,158,575.06, reflecting a growth of 27.09% from the end of the previous year[3]. - Total current assets as of September 30, 2021, amounted to CNY 1.64 billion, an increase of 10.27% from CNY 1.49 billion at the end of 2020[23]. - Total liabilities increased to CNY 1.52 billion, a significant rise of 83.96% from CNY 825.38 million at the end of 2020[24]. - Current liabilities totaled CNY 765,376,459.20, with a minor decrease of CNY 404,887.73[34]. - The company's equity attributable to shareholders was CNY 1,692,340,284.79, showing a decrease of CNY 482,930.39[35]. - The company reported a long-term investment of CNY 54,576,348.36, unchanged from the previous period[33]. Investments and Expenses - R&D expenses increased by 37.55% to ¥5,536.75 million due to the addition of new research projects[11]. - Research and development expenses increased to CNY 55.37 million, a rise of 37.59% compared to CNY 40.25 million in Q3 2020[26]. - Long-term borrowings surged by 763.04% to ¥43,236.00 million primarily for the construction of the Yaan urban sewage treatment facility PPP project[11]. - Investment income turned negative at -¥58.61 million, a decline of 138.48% compared to the previous period due to increased investment losses[11]. - Total operating costs for Q3 2021 were CNY 609.88 million, up from CNY 539.14 million in the same period last year, reflecting a growth of 13.06%[26]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 22,884[14]. - As of September 30, 2021, the total number of restricted shares was 202,211,509, with 31,105,448 shares released during the period[19]. - The company reported a total of 171,106,061 restricted shares remaining at the end of the period[19]. - The company has a total of 4,539,195 shares that are restricted due to fundraising for asset acquisition[18]. - The company has 13,634,389 shares restricted for fundraising related to asset acquisition, with a 12-month lock-up period[18]. Regulatory and Compliance - The report for the third quarter was not audited[36]. - The company decided to terminate the issuance of shares to specific targets and withdrew the application documents on July 7, 2021[20]. - The full subsidiary, Henan Tianrui Environmental Technology Co., Ltd., changed its business scope to include resource recycling services and environmental consulting[20]. - The company has implemented a new leasing standard effective from January 1, 2021, impacting the recognition of right-of-use assets and lease liabilities[35].

Financial Performance - The company's operating revenue for the first half of 2021 was ¥405,480,042.75, representing a 32.48% increase compared to ¥306,057,731.95 in the same period last year[22]. - The net profit attributable to shareholders of the listed company reached ¥14,883,480.37, a significant turnaround from a loss of ¥18,577,151.11 in the previous year, marking an increase of 180.12%[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥14,145,665.44, compared to a loss of ¥28,403,167.35 last year, reflecting a 149.80% improvement[22]. - The basic earnings per share were ¥0.0299, a recovery from a loss of ¥0.0402 per share in the same period last year, indicating a 174.38% increase[22]. - The total comprehensive income attributable to the parent company was CNY 14,883,480.37, compared to a loss of CNY 18,577,151.11 in the first half of 2020[179]. - The company reported a net profit of 149,454,384 CNY, reflecting a strong performance in its core business segments[75]. - The company reported a net loss of CNY 9,234,000 for the first half of 2021[192]. - The total comprehensive income for the period was reported at 7,151 million yuan, which is a decrease of 18.57% from the previous year[191]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,916,356,802.10, up 13.72% from ¥2,564,439,469.59 at the end of the previous year[22]. - The company's total assets as of June 30, 2021, amounted to CNY 2,916,356,802.10, an increase from CNY 2,564,439,469.59 at the end of 2020[165]. - The total liabilities rose to CNY 1,168,502,607.09 from CNY 825,379,245.12, indicating an increase of around 41.7%[167]. - The company's total liabilities decreased to CNY 539,596,312.17 from CNY 548,012,527.16 at the end of 2020, indicating improved financial stability[172]. - The total equity attributable to shareholders increased to CNY 1,939,880,228.87 from CNY 1,910,578,900.70 at the end of 2020, reflecting positive retained earnings[172]. Cash Flow - The net cash flow from operating activities was negative at -¥265,031,778.65, worsening from -¥91,269,185.74 in the same period last year, reflecting a decline of 190.38%[22]. - The company reported a significant decline in cash flow from operating activities, with a net outflow of ¥265,031,778.65, a decrease of 190.38% year-on-year, attributed to increased procurement for PPP projects[37]. - The company reported a net cash outflow from operating activities of CNY -265,031,778.65, worsening from CNY -91,269,185.74 in the first half of 2020[182]. - Cash and cash equivalents at the end of the first half of 2021 were CNY 269,467,155.97, down from CNY 455,222,662.28 at the beginning of the period[183]. Research and Development - Research and development expenses increased by 39.53% to ¥38,730,590.33, mainly due to an increase in R&D projects[37]. - The company has a strong R&D capability, continuously enriching its product range and expanding into new application areas[29]. - The company is focusing on the development of new technologies in wastewater treatment, with investments amounting to 20,000,000 CNY in related R&D activities[76]. - The company emphasized the importance of R&D investment to enhance core competitiveness and expand product lines in environmental monitoring, food safety, and medical testing[87]. Market and Business Strategy - The company plans to continue expanding its R&D efforts and is focusing on enhancing its product offerings in the environmental monitoring sector[37]. - The company plans to expand its market presence through the establishment of new subsidiaries, including Tianlan Xiangrui and Hunan Beixi, which are expected to contribute positively to future earnings[77]. - The company is actively pursuing mergers and acquisitions to strengthen its market position, having previously acquired 100% of Shanghai Beixi Biotechnology Co., Ltd. for 36,000,000 CNY[79]. - The company is committed to enhancing its service offerings in environmental monitoring and consulting, which are expected to drive future revenue streams[77]. Risks and Compliance - The management has highlighted potential risks and corresponding measures in the report, which investors are advised to review carefully[4]. - The company faced risks from intensified market competition and potential declines in gross margins due to price competition with foreign manufacturers[86]. - The company maintains compliance with national laws and regulations, focusing on both economic and social benefits[98]. - The company has not reported any significant mergers or acquisitions during this period, focusing instead on organic growth strategies[189]. Shareholder Information - The company completed a non-public issuance of 6,805,040 shares on January 12, 2021, increasing the total share capital from 490,185,830 to 496,990,870[128]. - The total number of ordinary shareholders at the end of the reporting period was 22,859[148]. - Liu Zhaogui, a major shareholder, holds 29.04% of the shares, totaling 4,326,306 shares, with a decrease of 9,939,817 shares during the reporting period[149]. - The company has not reported any strategic investors or general legal entities becoming top ten shareholders due to new share subscriptions[149]. Legal Matters - The company reported a total of 3,000,000 yuan involved in a lawsuit with Shenzhen Kangmei Biological Technology Co., Ltd., which is currently in the second instance of trial[107]. - Another lawsuit with Jiangxi Maiwang Environmental Technology Co., Ltd. involves 628,000 yuan and is awaiting further court hearings[107]. - The company has not faced any major litigation or arbitration matters during the reporting period[106]. Dividend Policy - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[6]. - The company did not distribute any dividends during this reporting period, maintaining a focus on reinvestment[189].

Financial Performance - The company's revenue for Q1 2021 was ¥209,411,764.69, representing a 44.67% increase compared to ¥144,755,161.80 in the same period last year[8] - Net profit attributable to shareholders decreased by 7.40% to ¥15,347,795.32 from ¥16,574,324.53 year-on-year[8] - The net profit excluding non-recurring gains and losses increased by 3.20% to ¥15,948,734.07 compared to ¥15,454,492.03 in the previous year[8] - Basic earnings per share decreased by 13.93% to ¥0.0309 from ¥0.0359 in the same period last year[8] - Diluted earnings per share also decreased by 13.93% to ¥0.0309 compared to ¥0.0359 in the previous year[8] - The weighted average return on equity was 0.90%, down from 1.03% in the same period last year[8] - Operating profit reached CNY 21.15 million, up 28.26% year-over-year[23] - Net profit attributable to the parent company was CNY 15.35 million, a decrease of 7.40% from the previous year, primarily due to increased operating and R&D expenses[23] - The company reported a total operating revenue of CNY 209.41 million, an increase of 44.67% compared to the same period last year[21] Cash Flow and Assets - The net cash flow from operating activities improved by 64.35%, reaching -¥23,443,996.87, compared to -¥65,767,787.93 in the same period last year[8] - Cash inflow from operating activities totaled CNY 298.73 million, a 61.93% increase, attributed to higher sales collections[21] - Cash outflow from operating activities was CNY 322.18 million, up 28.74%, mainly due to increased procurement costs[21] - The company reported a net cash flow from operating activities of CNY -23.44 million, an improvement of 64.35% compared to the previous year[21] - Cash flow from operating activities was CNY 282,992,682.60, compared to CNY 155,854,310.65 in the previous period, showing an increase of approximately 81.6%[66] - The company's total current assets as of March 31, 2021, amounted to CNY 1,606,850,215.56, an increase from CNY 1,486,097,288.03 on December 31, 2020, reflecting a growth of approximately 8.1%[48] - Cash and cash equivalents decreased to CNY 438,516,403.86 from CNY 462,696,662.28, representing a decline of about 5.2%[49] - The company reported a total cash outflow from investing activities of 257,218,608.36 CNY, significantly higher than 37,820,432.38 CNY in the previous period, indicating increased investment activities[67] Research and Development - R&D expenses surged to CNY 18.92 million, reflecting a 99.01% increase year-over-year, driven by the expansion of R&D projects[21] - Research and development expenses rose significantly to CNY 18,920,039.36, compared to CNY 9,507,210.62 in the same period last year, reflecting a growth of approximately 99.5%[59] - The company is in the prototype testing phase for several new products, including the GC-MS 6800 and POW-II systems, with ongoing tests expected to continue[23] - The company is in the process of clinical evaluation for various hormone test kits, including testosterone and progesterone[25] - The company has completed the engineering prototype preparation for several immunoassay kits, which are currently undergoing registration inspection[26] Shareholder and Market Activities - The total number of shares held by major shareholders is 170,776,061, with 6,805,040 shares subject to lock-up restrictions[18] - The company has a total of 75% lock-up on shares for executives during their tenure, with specific unlock schedules based on the issuance date of new shares[16] - The company is actively managing its share structure to align with strategic growth initiatives and investor confidence[20] - The company is focusing on enhancing its marketing system to increase market share, particularly in sectors like environmental protection and food safety[29] - The company is transitioning its overseas business promotion and after-sales service from offline to online platforms, adapting to current market conditions[30] Investments and Acquisitions - The company has issued shares for asset acquisitions, with a total of 13,634,389 shares involved in these transactions[18] - The acquisition of Suzhou Tianrui Environmental Technology Co., Ltd. was completed with an investment of 81.78 million, achieving 84.09% of the planned investment[38] - The acquisition of Shanghai Beixi Biological Technology Co., Ltd. was fully paid with an investment of 360 million, achieving 100% of the planned investment[38] - The company plans to use excess raised funds for various strategic investments, including loan repayment and working capital supplementation[39] Environmental and Technological Development - The company is advancing its technology development in various environmental applications, including zero discharge technology for tin-containing wastewater and modular artificial wetland systems for rural wastewater treatment[27] - The company has successfully completed projects related to soil contaminant analysis, including the determination of phthalate content and ammonia nitrogen uncertainty assessment[27] - The company has established a technical development phase for the analysis of volatile halogenated hydrocarbons in fixed pollution sources, reflecting its commitment to air quality monitoring[27] Risks and Challenges - The company faces risks from intensified market competition and potential declines in gross margins due to price competition with foreign manufacturers[32] - The company emphasizes continuous investment in R&D to mitigate risks associated with new product launches not meeting expectations[32] - The company is committed to optimizing its organizational structure and enhancing human resource management to improve operational efficiency[30]

Financial Performance - The company's operating revenue for 2020 was ¥935,696,717.93, representing a 3.07% increase compared to ¥907,813,927.42 in 2019[18]. - The net profit attributable to shareholders for 2020 was ¥21,105,083.14, a slight increase of 0.24% from ¥21,055,068.78 in 2019[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥36,084,485.26, a significant decrease of 2,003.03% from -¥1,715,833.61 in 2019[18]. - The net cash flow from operating activities increased by 609.05% to ¥138,859,567.05 in 2020, compared to ¥19,583,778.92 in 2019[18]. - Total assets at the end of 2020 were ¥2,564,439,469.59, an 18.97% increase from ¥2,155,458,160.93 at the end of 2019[18]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion yuan, representing a year-over-year growth of 20%[39]. - The company reported a total revenue of approximately CNY 1.5 billion for the year 2020, reflecting a year-on-year growth of 15%[48]. - The company achieved a net profit of around CNY 300 million, representing an increase of 20% compared to the previous year[48]. Risk Management - The company emphasizes that all board members attended the meeting to review the annual report, ensuring accountability for the report's accuracy and completeness[3]. - The company has outlined potential risks and countermeasures in the section discussing future development prospects[4]. - The company has a comprehensive risk management strategy in place to address operational challenges[4]. - The company faces risks from intensified market competition and potential underperformance of new product promotions, which could impact profit margins[164]. - The company emphasizes the importance of internal control and operational management to mitigate risks associated with increased external investments in environmental governance[165]. Research and Development - The company is actively investing in R&D, with a budget allocation of 100 million yuan for the development of new technologies and products in 2021[37]. - The company has achieved a patent portfolio of over 50 new patents in 2020, reflecting its commitment to innovation and technology advancement[37]. - The company has obtained a total of 322 authorized patents, enhancing its competitive edge in the industry[35]. - The company is focusing on the development of new technologies such as ozone catalytic oxidation for wastewater treatment, which meets the stringent surface water Class V standards[68]. - The company has made significant progress in the clinical evaluation of various chemical luminescence immunoassay test kits, indicating a strong pipeline of diagnostic products[98]. Market Expansion - The company plans to expand its market presence in Southeast Asia, targeting a 25% increase in market share within the next two years[41]. - Future outlook indicates a projected revenue growth of 10% for 2021, driven by new product launches and market expansion strategies[41]. - The company is exploring potential mergers and acquisitions to strengthen its product portfolio and market share, with a focus on complementary technologies[36]. - The company is actively engaged in the research and development of new environmental technologies, enhancing its competitive edge[141]. - The company is exploring market expansion opportunities through strategic acquisitions and partnerships in the environmental protection sector[116]. Product Development - New product development includes the launch of a fully automated drug residue detection instrument, which is expected to enhance market competitiveness[39]. - The company has introduced several new products, including a portable vacuum bag sampler and a nitrogen generator, which are expected to enhance market competitiveness[36]. - New product development includes a series of wastewater treatment systems, with an expected launch in Q3 2021, aimed at addressing industrial waste management needs[41]. - The company is in the prototype phase for several new products, including the GC-MS 6800 and the POW-I water quality system, with ongoing testing and development[93]. - The company has successfully completed several projects related to wastewater treatment technologies, including nickel ion treatment and recovery processes, demonstrating its commitment to environmental sustainability[99]. Corporate Governance - The company has fulfilled all commitments made by actual controllers and shareholders during the reporting period[175]. - The company has a tax reduction benefit of CNY 17.0583 million due to local tax policies[178]. - The company has established a comprehensive patent layout to protect its existing intellectual property rights[161]. - The company has a strong emphasis on research and development, as evidenced by the numerous patents granted in recent years[50]. - The company has established a robust intellectual property portfolio, which is essential for protecting its innovations and market position[50]. Financial Strategy - The company reported a profit distribution plan of 0.09 RMB per 10 shares (including tax) based on a total of 496,990,870 shares[4]. - The proposed cash dividend for 2020 is CNY 0.09 per 10 shares, totaling CNY 4.4729 million[173]. - The cash dividend payout ratio for 2020 is 21.19% of the net profit attributable to shareholders[174]. - The company plans to allocate CNY 12.8908 million to statutory surplus reserves from the 2020 profit[172]. - The remaining distributable profit for shareholders after the 2020 dividend distribution is CNY 32.22342 million[172].

Financial Performance - Net profit attributable to shareholders increased by 555.33% to CNY 41,329,139.95 for the reporting period[7] - Operating income for the reporting period was CNY 235,636,616.27, representing a year-on-year increase of 14.98%[7] - Basic earnings per share rose by 554.33% to CNY 0.0895[7] - The company reported a decrease of 8.46% in total operating income for the year-to-date period, totaling CNY 541,694,348.22[7] - The company's total operating revenue for the first nine months of 2020 was CNY 541.69 million, a decrease of 8.46% compared to the same period last year[22] - Operating income from non-operating activities was 1.17 million yuan, up by 441,400 yuan year-on-year, with a growth rate of 60.25% due to increased government subsidies[25] - The total profit for the third quarter was CNY 35.16 million, compared to CNY 32.41 million in the previous year, reflecting an increase of 8.5%[54] - The company reported a net profit of CNY 393,168,119.63 in retained earnings, compared to CNY 317,700,902.72 in the previous period[42] - The company reported a significant increase in asset disposal gains, which reached CNY 44.85 million compared to CNY 0.32 million in the previous year[54] Cash Flow and Liquidity - Net cash flow from operating activities increased by 240.96% to CNY 29,566,125.35[7] - Total cash inflow from operating activities was 711.84 million yuan, a decrease of 8.89% compared to the previous year, primarily due to reduced sales revenue[26] - Total cash outflow from operating activities was 773.54 million yuan, down by 7.62% year-on-year, mainly due to reduced procurement and tax payments[27] - Cash inflow from investment activities decreased by 29.85% to 184.55 million yuan, primarily due to reduced returns from financial product investments[27] - Cash inflow from financing activities increased significantly by 197.96% to 276.19 million yuan, mainly due to increased working capital loans[27] - The net increase in cash and cash equivalents was a decrease of 620.28 million yuan, down by 30.81% year-on-year[27] - The total cash and cash equivalents at the end of the period were 276,310,371.77 CNY, down from 277,436,508.51 CNY in the previous period[63] - The company reported a cash outflow of 184,367,700.48 CNY related to other operating activities, slightly up from 176,119,685.90 CNY[62] Assets and Liabilities - Total assets increased by 6.53% to CNY 2,296,253,902.95 compared to the end of the previous year[7] - The total assets of the company as of September 30, 2020, amounted to CNY 2,341,610,949.63, compared to CNY 1,941,486,047.58 at the end of 2019[42] - The total liabilities increased to CNY 501,370,860.60 from CNY 321,537,154.09 in the previous period[42] - Owner's equity totaled CNY 1,690,281,148.25, including CNY 461,760,000.00 in share capital and CNY 323,254,643.87 in undistributed profits[71] - The total liabilities to equity ratio stands at approximately 27.5%, indicating a low leverage level[71] Shareholder Information - The company has a total of 22,695 common shareholders at the end of the reporting period[11] - The largest shareholder, Liu Zhaogui, holds 33.41% of the shares, totaling 154,266,123 shares[11] Research and Development - Research and development expenses decreased by 21.12% to CNY 40.25 million, primarily due to reduced R&D investment by the parent company and its subsidiary[23] - Research and development expenses for the third quarter were CNY 25.96 million, down from CNY 32.26 million, indicating a decrease of 19.5%[57] Other Income and Expenses - Non-recurring gains and losses amounted to CNY 50,795,236.42, with significant contributions from government subsidies and asset disposals[9] - Income tax expenses increased to 15.56 million yuan, up by 8.76 million yuan year-on-year, reflecting a growth of 128.88% due to increased profits from asset disposals[25] - The company recognized other income of CNY 25.30 million, an increase of 20.58% compared to the previous year, mainly from the acceptance of research project revenues[24] Credit and Asset Impairment - The company reported a significant increase in credit impairment losses, which rose by 153.67% to CNY 34.81 million, due to a decrease in cash collection from sales[24] - The company experienced a credit impairment loss of CNY 34.81 million, compared to CNY 13.72 million in the previous year, indicating a significant increase in credit risk[54] - The company's asset impairment losses amounted to CNY 4.43 million, primarily due to the provision for inventory write-downs[24] Future Outlook - The company plans to continue focusing on market expansion and new product development to drive future growth[57]

Financial Performance - The company's operating revenue for the first half of 2020 was approximately ¥306.06 million, a decrease of 20.87% compared to ¥386.79 million in the same period last year[19]. - The net profit attributable to shareholders of the listed company was a loss of approximately ¥18.58 million, a decline of 163.63% compared to a profit of ¥29.20 million in the previous year[19]. - The net cash flow from operating activities was a negative ¥91.27 million, worsening by 160.45% from a negative ¥35.04 million in the same period last year[19]. - The basic earnings per share were -¥0.0402, a decrease of 163.61% from ¥0.0632 in the previous year[19]. - The company reported a net profit excluding non-recurring gains and losses of approximately -¥28.40 million, a decline of 207.18% compared to ¥26.50 million in the previous year[19]. - The main reason for the decline in revenue was the impact of the COVID-19 pandemic, which delayed the resumption of work for the company and its upstream and downstream enterprises[44]. - The company reported a significant increase in credit impairment losses during the reporting period, impacting net profit by CNY 25.04 million compared to the same period last year[44]. - The company reported a net profit of 34.754 million yuan for the first half of 2020, with a total revenue of 76.16 million yuan, indicating a 0% growth compared to the previous period[77]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥2.19 billion, an increase of 1.80% from ¥2.16 billion at the end of the previous year[19]. - The net assets attributable to shareholders of the listed company were approximately ¥1.58 billion, a decrease of 1.69% from ¥1.60 billion at the end of the previous year[19]. - The company's cash balance decreased by 1.98 million yuan, a reduction of 7.48%, mainly due to payments for water service investments[37]. - As of the end of the reporting period, cash and cash equivalents amounted to CNY 244.62 million, a decrease of 7.48% compared to CNY 264.41 million in the same period last year, primarily due to increased investment expenditures[52]. - Total liabilities at the end of the period were CNY 3,905,600 million, reflecting a stable financial position[187]. Investments and Acquisitions - The company has made significant investments in R&D to enhance product performance and increase added value, aligning with customer needs[27]. - The company has entered new fields such as environmental governance and medical instrument manufacturing through mergers and acquisitions[26]. - The company acquired a 62.84% stake in Shanghai Pan Instrument Co., with an investment amount of ¥998,630, focusing on environmental monitoring and testing[58]. - The company completed an investment of ¥11,478,400 in Henan Tianrui Environmental Technology Co., acquiring a 100% stake in solid waste management services[62]. - The company used 360 million RMB of raised funds to acquire 100% equity of Shanghai Beixi Biotechnology Co., making it a wholly-owned subsidiary[85]. - The company acquired 51% equity of Jiangsu Guoce Testing Technology Co. for 43.71 million RMB, establishing it as a controlling subsidiary[86]. Market Position and Strategy - The company has established a strong market presence, exporting products to over 100 countries and regions, including the USA, Germany, and Australia[27]. - The company is positioned as a leader in the chemical analysis instrument industry, focusing on high-end analytical instruments such as spectrometers and chromatographs[26]. - The domestic POCT market is experiencing rapid growth, with the company’s subsidiary, Bexi Bio, specializing in rapid diagnostic reagents and instruments[30]. - The company has achieved a strong industry position in the XRF field, with a competitive advantage in technology, talent, and marketing networks[31]. - The company is focusing on long-term investments in environmental protection and wastewater treatment sectors[61]. - The company plans to expand its product offerings in environmental protection technology and consulting services[60]. Research and Development - The company is actively engaged in the research and development of new technologies, including matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF) instruments[78]. - Research and development expenses decreased by 13.21% to CNY 27.76 million compared to the previous year[46]. - The company continues to invest in R&D to enhance core competitiveness and expand product lines in environmental monitoring and medical testing[92]. Operational Challenges - The company faced significant operational risks and has outlined measures to address these risks in the report[5]. - The company emphasizes the risk of declining gross margins due to intensified market competition and low-price competition with foreign manufacturers[91]. - The overall financial condition reflects challenges, with some subsidiaries experiencing losses while others show modest profits[80]. - The overall performance of subsidiaries indicates a need for strategic adjustments to improve profitability and operational efficiency[81]. Legal and Compliance Issues - The company has ongoing litigation related to various contract disputes, with amounts involved including 197.6 million yuan and 18 million yuan[103]. - The company faced a fine of RMB 40.2 million for customs violations related to the import of 50 units of optical spectrum detection modules, with a total declared value of USD 95,550[108]. - The company has implemented corrective measures to ensure compliance with customs regulations, including strengthening the review process for customs documentation[110]. Future Outlook - Future guidance suggests a focus on innovation and market expansion to drive revenue growth and enhance competitive advantage[82]. - The company has plans for market expansion and new product development to enhance future growth prospects[192]. - The company aims to improve operational efficiency through strategic initiatives and technological advancements in the upcoming quarters[192].